Diagonal Bio enters into a strategic partnership with Daniel Redén at StallZet to enhance commercialisation plans
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that Daniel Redén, a renowned horse trainer at StallZet, has entered into a partnership with Diagonal Bio and will act as a marketing partner for the Company to enhance the commercialisation plans for the Company’s platform, LAMPlify®️. StallZet, one of Sweden's leading trotting facilities with over 190 horses, is collaborating with Diagonal Bio in the ongoing pilot test of LAMPlify®️. As a marketing partner to Diagonal Bio, Daniel Redén will play a key role in showcasing the benefits of LAMPlify® and promoting the product. His extensive experience and wide-ranging network within the trotting and equestrian industries, both nationally and internationally, make him a valuable addition to Diagonal Bio’s commercialisation plans.
Press release
December 23, 2024
With over 1,000 training victories under his belt, and a wide international presence, including breeding horses in the United States and competing in France, the partnership with Redén provides an excellent opportunity to showcase LAMPlify® to an important target audience including Key Opinion Leaders during 2025.
"I am honoured to become an ambassador for Diagonal Bio. The company’s work to provide accurate and fast diagnostic solutions for horses is revolutionary and has the potential to raise the standard of animal welfare worldwide. I look forward to working together to spread awareness about LAMPlify® and its ability to transform how we manage horse health," - Daniel Redén, horse trainer at StallZet
"Daniel Redén's dedication and expertise in the trotting industry will help us reach as many Key Opinion Leaders in the equestrian sector as possible and demonstrate how LAMPlify® can enhance the health and safety of horses worldwide," - Karin Wehlin, CEO at Diagonal Bio AB (publ)
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on December 23, 2024, at 21:45 CET.
For additional information about, please contact:
Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.